Monday April 27, 2026
This week doesn’t hinge on a single trend — it’s a stacked signal. Policy is finally catching up to innovation, capital is concentrating around platforms (AI, robotics, noninvasive therapy), and regulatory momentum is quietly reshaping how fast devices actually reach patients.
We have a quick poll halfway through this week's issue — we'd love your input on what content matters most to you.
8 things to watch this week:
1. 🏛️ CMS & FDA Launch RAPID Coverage Pathway for Breakthrough Devices
CMS and FDA jointly unveiled the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway, which could compress Medicare coverage timelines for breakthrough devices from over a year down to as little as two months. Roughly 40 existing devices qualify immediately — and with permanent Medicare coverage on offer (not the four-year window of prior programs), this fundamentally changes the commercial calculus for companies building toward a breakthrough designation.
FierceHealthcare
2. 🎯 86% of Medtech Teams Make Claims Their Evidence Can’t Back Up
In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.
We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.
If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, take two minutes to see where you stand.
Take the free readiness check →
Sponsored
3. 🤖 Intuitive Surgical Posts Blowout Q1, Raises Full-Year Guidance
Intuitive reported $2.77B in Q1 revenue (+23% YoY), beating consensus by ~5.5%, with EPS of $2.50 crushing estimates by nearly 17%. Da Vinci procedure volume grew 16% and Ion surged 39%. Management raised its full-year procedure growth outlook and shares jumped more than 7% — the clearest signal yet that surgical robotics demand is not slowing down.
Proactive Investors
4.📉 Boston Scientific Slashes 2026 Guidance Despite Solid Q1
BSX posted solid Q1 revenue of $5.2B (+11.6%), but dramatically cut its full-year sales growth forecast from 10.5–11.5% down to 7–8.5%, citing unexpected headwinds in its Farapulse PFA platform, Watchman, and Urology franchises. Competitors Medtronic, J&J MedTech, Abbott, and Kardium are all gaining ground in electrophysiology — and CEO Mike Mahoney called the guide-down something the company was “not proud of.”
MedTech Dive
Before we continue — quick question for you:
Thanks — now back to the news.
5. 💊 Johnson & Johnson MedTech Grows 4.6% in Q1, Raises Full-Year Guidance
J&J’s MedTech segment posted $8.6B in Q1 sales with 4.6% operational growth, driven by cardiovascular, surgery, and vision. The company raised its full-year 2026 operational sales guidance to 5.9–6.9%, targeting $100B+ in total company revenue — and its OTTAVA robotic surgery system is now a credible threat to Intuitive Surgical in the multi-port segment by late 2026.
Yahoo Finance / GuruFocus
6. 🤝 Stryker Acquires Amplitude Vascular; Avanos Goes Private in Active M&A Week
Stryker announced its acquisition of Amplitude Vascular Systems (IVL-based vascular technology) in a week that also saw Avanos Medical agree to be taken private at a 72% premium. Zooming out: Q1 2026 medtech M&A totaled $26.6B across 37 deals — with deal flow accelerating around surgical robotics, cardiovascular, and diagnostics — signaling that strategic portfolio reshaping remains a defining theme of the year.
FierceBiotech / J.P. Morgan
7. ⚠️ FDA Issues Class I Recall for Tandem Mobi Insulin Pumps Over Software Flaw
The FDA classified a software correction for Tandem’s Mobi insulin pump as a Class I recall — its most serious designation. A false motor detection error can halt insulin delivery entirely, risking severe hyperglycemia. Over 17,700 devices are affected and users are urged to update to software version 7.9.0.2 immediately. This is the latest in a string of diabetes device safety actions from the FDA in 2026, including a prior Insulet Omnipod 5 recall in March.
MedTech Dive / FDA
8.💡 AcuityMD Raises $80M Series C, Valued Near $1B
AcuityMD, the AI commercial intelligence platform used by 16 of the top 20 medtech companies, raised $80M in a Series C led by StepStone Group. The company — which has helped customers identify more than $34B in pipeline opportunities — plans to accelerate agentic AI for sales and marketing teams and expand beyond commercial use cases across the full product lifecycle. With the medtech sector increasingly competing on commercial execution, this signals where the next wave of operational investment is headed.
The AI Insider
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.